# US 2003/0073237 A1 · Gene therapy to promote angiogenesis and/or the treatment of heart failure

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0073237 A1
- Document ID: US20030073237A1
- Status: Published application
- Kind: A1
- Application number: 10/189,809
- Filed: 2002-07-03
- Published: 2003-04-17
- Earliest claimed: 2000-01-13
- Inventors: Antonius Jacobus M. Roks; Yigal-Martin Pinto; Robert Henk Henning; Wiekert Hendrikus van Gilst
- Web page: https://patentgrep.com/patent/US20030073237A1

## CPC

- A61K 38/085: {Angiotensins}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Nucleic acid delivery vehicles for enhancing and/or inducing angiogenesis are provided. The delivery vehicles comprise a nucleic acid encoding angiotensin 1-7 or a functional part, derivative and/or analogue thereof. The vehicles are among others suited for the treatment of heart failure.

## Claims

### Claim 1

A nucleic acid delivery vehicle for enhancing and/or inducing angiogenesis, said nucleic acid delivery vehicle comprising:
a nucleic acid comprising at least one sequence encoding an angiotensin 1-7 or a functional part, derivative and/or analogue thereof, and
a nucleic acid carrier.

### Claim 2 (depends on 1)

The nucleic acid delivery vehicle of claim 1, further comprising at least one sequence encoding an additional angiogenesis promoting factor.

### Claim 3 (depends on 2)

The nucleic acid delivery vehicle of claim 2, wherein said additional angiogenesis promoting factor is selected from the group consisting of VEGF, bFGF, angiopoietin-1, and a nucleic acid encoding a protein capable of promoting nitric oxide production.

### Claim 4 (depends on 1, 2, 3)

The nucleic acid delivery vehicle of claim 1, claim 2, or claim 3, wherein the expression of at least one sequence is regulated by a signal.

### Claim 5 (depends on 4)

The nucleic acid delivery vehicle of claim 4, wherein said signal is provided by oxygen tension.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The nucleic acid delivery vehicle of any of claim 1, claim 2, claim 3, claim 4, or claim 5 wherein said nucleic acid delivery carrier is selected from the group consisting of a liposome, a virus particle, and a functional analogue or derivative thereof.

### Claim 7 (depends on 6)

The nucleic acid delivery vehicle of claim 6, wherein said nucleic acid delivery carrier comprises a Semliki Forest virus vector, an adenovirus vector or an adeno-associated virus vector.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

A method for enhancing and/or inducing angiogenesis, said method comprising:
providing cells of a subject with the nucleic acid delivery vehicle of any of claims 1-7.

### Claim 9 (depends on 8)

The method according to claim 8, wherein said enhancing and/or inducing angiogenesis effect is at least partly reversible.

### Claim 10 (depends on 9)

The method according to claim 9, wherein said effect is at least in part reversed through an increase in the oxygen tension or through providing said cells with gancyclovir or a functional analogue thereof, or both.

### Claim 11 (depends on 8, 9, 10)

The method according to any one of claims 8-10, wherein said cells comprise at least cells that under normal circumstances are not in direct contact with blood.

### Claim 12 (depends on 11)

The method according to claim 11, wherein said cells are muscle cells.

### Claim 13 (depends on 12)

The method according to claim 12, wherein said muscle cells are cardiac or skeletal muscle cells.

### Claim 14 (depends on 12)

The method according to claim 12, wherein said cells are smooth muscle cells.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A method of treating endothelial dysfunction in a subject, said method comprising administering to the subject the nucleic acid delivery vehicle of any one of claims 1-7 or practicing the method according to any one of claims 8-14 on the subject.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7)

A cell for the production of the nucleic acid delivery vehicle of any one of claims 1 to 7, said cell comprising means for producing virus vector in the absence of replication competent adenovirus and adeno-associated virus.

### Claim 17 (depends on 16)

The cell of claim 16, wherein said cell expresses at least one means for the production of said virus vector from a nucleic acid integrated in the chromosomal DNA of said cell and expresses other means for producing of said virus vector from nucleic acid not integrated in the chromosomal DNA of said cell and wherein said integrated nucleic acid and said non-integrated nucleic acid do not comprise sequence overlap leading to the formation of replication competent adenovirus.

### Claim 18 (depends on 17)

The cell of claim 17, wherein said integrated nucleic acid comprises at least an adenovirus E1-region or a functional analogue or a derivative thereof.

### Claim 19 (depends on 17, 18)

The cell of claim 17 or claim 18, wherein said integrated nucleic acid comprises at least a sequence encoding an adenovirus E2A protein, preferably an E2A-protein derived from adenovirus ts125 or functional analogues or derivatives thereof.

### Claim 20 (depends on 17, 18, 19)

The cell of any one of claims 17-19, wherein said integrated nucleic acid comprises at least an adenovirus E4-region, preferably E4-orf6, or a functional analogue or a derivative thereof.

### Claim 21 (depends on 17, 18, 19, 20)

The cell of any one of claims 17-20, wherein said cell is derived from a PER.C6 cell (ECACC deposit number 96022940).
